Kenvue Inc. (NYSE:KVUE) Shares Sold by Equity Investment Corp

Equity Investment Corp trimmed its stake in shares of Kenvue Inc. (NYSE:KVUE) by 2.3% during the fourth quarter, Holdings Channel reports. The firm owned 6,417,639 shares of the company’s stock after selling 152,903 shares during the period. Kenvue comprises about 3.2% of Equity Investment Corp’s holdings, making the stock its 5th largest position. Equity Investment Corp’s holdings in Kenvue were worth $137,017,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. AMF Tjanstepension AB grew its position in shares of Kenvue by 187.3% during the third quarter. AMF Tjanstepension AB now owns 120,477 shares of the company’s stock worth $2,787,000 after acquiring an additional 78,540 shares during the last quarter. International Assets Investment Management LLC grew its position in Kenvue by 1,529.5% in the 3rd quarter. International Assets Investment Management LLC now owns 106,341 shares of the company’s stock worth $2,460,000 after purchasing an additional 99,815 shares during the last quarter. Allworth Financial LP increased its stake in shares of Kenvue by 5.9% in the third quarter. Allworth Financial LP now owns 20,023 shares of the company’s stock valued at $463,000 after purchasing an additional 1,113 shares during the period. Nisa Investment Advisors LLC raised its holdings in shares of Kenvue by 28.0% during the third quarter. Nisa Investment Advisors LLC now owns 228,598 shares of the company’s stock valued at $5,287,000 after buying an additional 50,073 shares during the last quarter. Finally, abrdn plc raised its holdings in shares of Kenvue by 298.7% during the third quarter. abrdn plc now owns 708,047 shares of the company’s stock valued at $16,409,000 after buying an additional 530,444 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently commented on the company. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and lowered their target price for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Royal Bank of Canada reissued a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a report on Monday, February 3rd. Barclays reduced their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. UBS Group lowered their target price on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday, February 7th. Finally, Citigroup dropped their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $23.08.

Kenvue Trading Down 0.6 %

Shares of NYSE:KVUE opened at $23.22 on Thursday. The stock has a market capitalization of $44.52 billion, a price-to-earnings ratio of 43.81, a PEG ratio of 2.62 and a beta of 1.45. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The company has a 50 day moving average price of $21.36 and a 200 day moving average price of $22.23. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were issued a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.53%. Kenvue’s payout ratio is presently 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.